An experimental treatment happens to be the solution to delay Alzheimer's symptoms in some people. These people are the ones who are genetically destined to get the disease in their 40s or 50s. These new findings form ongoing research has now been caught up in Trump administration funding delas. The early results of the study has been published on Wednesday and the participants too are worried that politics could cut their access to a possible lifeline.

One of the participants had said, "It is still a study but it has given me an extension to my life that I never banked on having." The participant is named Jake Henrichs, form New York City, who is 50 years old. He is one of them to be treated in that study for more than a decade now and has remained symptom-free despite inheriting an Alzheimer's-causing gene that had killed his father and brother around the same age.

Slowing Down The Symptoms

Two drugs which can modestly slow down early-stage Alzheimer's are sold in the United States. These drugs clear the brain of one of its hallmarks, a sticky gunk-like part called the amyloid. However, there have not been any hints that removing amyloid far earlier, way many years before the first symptoms appear, may postpone the disease.

How Was The Research Conducted?

The research is led by Washington University in St Louis, which involved families that passed down rare gene mutation as participants. This meant it was almost guaranteed that they will develop symptoms at the same age their affected relatives did.

The new findings is based on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset. The study is published in the journal Lancet Neurology.

Washington University's Dr Randall Bateman, who directs the Dominantly Inherited Alzheimer's Network of studies involving families with these rare genes says, "What we want to determine over the next five years is how strong is the protection. Will they ever get the symptoms of Alzheimer’s disease if we keep treating them?”

The researchers before though did not know what exactly caused Alzheimer's which affects nearly 7 million Americans, most of them in their later life. However, it is clear that these silent changes occur in the brain at least two decades before the first symptom shows up. The big contributor. At some point amyloid buildup can trigger a protein named tau that then starts to kill neurons, which can lead to cognitive decline.

Researchers are now thus studying the Tau-fighting drugs and are looking into other factors, like inflammation, brain's immune cells and certain virus.

The National Institute of Health (NIH) has expanded its focus as researchers have found more reasons for Alzheimer's. In 2013, the NIH's National Institute on Aging funded 14 trials of possible Alzheimer's drugs over a third targeting amyloid. By last fall, there were 68 drugs and 18% of them target amyloid. However, there are scientists too who think that amyloid is not everything and their is way more in the brain tissue, immune cells, and more which can be studied.

Doctors may soon be able to determine a brain tumour’s type right during the surgery. Doctors remove a tissue sample during surgery to analyse the tumour. Patients undergoing surgery for brain tumour may not have to wait days or weeks to find out.

A new rapid genetic test being tested by the NHS in England promises to shorten the wait time drastically. The technology can find the precise type of brain tumour within about two hours, while the patient is still on the operating table.

Developed by researchers at the University of Nottingham and Nottingham University Hospitals NHS Trust, the test analyses the genetic code of a tumour sample rather than relying only on traditional microscopic examination.

Brain Tumour Diagnosis Takes A Long Time

Brain tumours are not connected to one single disease. There are more than 100 types, ranging from relatively slow-growing tumours to highly aggressive cancers. Knowing the exact type and characteristics of a tumour is important because treatment courses can differ significantly.

Traditionally, doctors take a sample during surgery and send it to a pathology laboratory. The tissue sample is then examined under a microscope. Finding out the tumour type usually takes weeks.

According to an NHS centre, the current average time for a brain tumour diagnosis can be around 26 days, while other reports have estimated up to almost eight weeks in some cases. In case of aggressive tumours, waiting period can be particularly difficult and longer.

Also read: Rabies Day Exclusive: ‘We Need To Target The Source’ For A Rabies-Free India By 2030, Says Veterinary Epidemiologist

More About The New Test

The rapid genomic test works by analysing a small piece of the tumour which is taken during the surgery and sent to the laboratory, where its DNA is analysed using a shoebox-sized sequencing machine developed by Oxford Nanopore.

Inside the machine, DNA molecules pass through tiny pores. As they move through, the system reads their genetic information and uses the resulting genomic pattern to identify the tumour type.

Marking a significant jump in speed and time taken, the test can help doctors can receive detailed diagnosis during the operation itself instead of weeks.

Also read: Radiotherapy Cuts Risk Of Atypical Meningioma Recurrence By Nearly Half: Lancet Study

Promising Development In Brain Tumour Diagnosis

Not only this test reduces weeks, sometimes months of anxiety, it can also help surgeons make immediate decisions about how much tumour tissue to remove while protecting healthy brain tissue.

Some tumour types require different surgical approaches, and having molecular information immediately could help the surgeon take quick decisions.

A rapid diagnosis can also help patients to begin the appropriate treatment sooner and gain earlier access to clinical trials designed for specific tumour types.

The NHS is piloting the technology to determine how well rapid genomic testing works in routine clinical practice. The initial rollout covers five specialist centres, including Nottingham University Hospitals, University Hospitals Birmingham, Great Ormond Street Hospital, King's College Hospital and Newcastle Hospitals. More centres are expected to be added soon.

The rapid testing is therefore intended to complement the entire diagnostic process rather than make traditional pathology obsolete. If the NHS pilot is successful, rapid genomic testing could eventually make that information available much earlier to brain tumour patients across England.

The early signs of type 2 diabetes could be related to your gut. They may signal a warning risk long before you take a blood sugar test.

New research suggests that changes in the trillions of bacteria living in the gut may accurately predict future diabetes risk.

An analysis of microbiome data from more than 229,000 adults in the UK and US identified hundreds of bacterial changes linked with type 2 diabetes, including changes that appeared before measurable abnormalities in blood glucose.

The findings are being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan.

What Did Researchers Find?

Researchers from the University of Trento in Italy and collaborators in the UK analysed metagenomic data, which involves examining the DNA of microorganisms living in the gut.

The study included 229,025 people, of whom 3,627 had type 2 diabetes, 14,022 had prediabetes and 211,376 had normal blood glucose levels. The average age was 50, and about 74% of participants were women.

After accounting for factors including age, sex and body mass index, researchers identified 789 bacterial species associated with type 2 diabetes.

Of these, 168 were found at higher levels in people with diabetes, while 621 were present at lower levels.

One example was Enterocloster bolteae, which was more abundant in people with type 2 diabetes. In contrast, Romboutsia timonensis was found at lower levels.

Interestingly, 587 of the 789 bacterial species were also associated with unmedicated prediabetes, suggesting that some of these microbial changes may occur before diabetes is diagnosed.

Also read: Diabetes Linked To 55% Risk Of Kidney Disease, Heart Failure Or Death Within 10 Years: Study

Link Between Gut & Blood Sugar

The researchers looked at 135,093 people who had normal blood glucose and did not have diabetes or prediabetes. They also had information about how their blood sugar responded after eating.

Normally, blood glucose rises after a meal and then falls. If it remains elevated for longer than expected, it can indicate that the body's muscles are not responding properly to insulin, an early feature of insulin resistance.

Researchers found that people whose blood sugar remained elevated for longer were more likely to have the gut bacterial pattern linked with type 2 diabetes. The microbiome changes became more pronounced as insulin resistance increased.

Therefore, it was observed that the gut microbiome carried clues about metabolic problems even when standard blood glucose levels were still normal.

Also read: Muscle Loss In Middle Age May Signal Dementia Risk, Study Finds

Future Of Diabetes Testing

Currently, diabetes and prediabetes are diagnosed using tests like HbA1c, fasting blood glucose and oral glucose tolerance tests.

For people who have normal results, doctors generally assess future diabetes risk using factors like age, sex, body mass index and family history. A gut microbiome test is not currently part of routine diabetes screening.

The researchers believe microbiome analysis could eventually provide an additional layer of risk assessment, identifying people who could benefit from earlier lifestyle interventions.

Professor Tim Spector, one of the study's authors, Scientific Co-Founder, ZOE, said, “These latest findings represent a major step forward in understanding how our gut microbiome is linked directly with metabolic disease. Identifying these clear microbial changes before blood sugar levels worsen could lead to earlier intervention with food and lifestyle choices, as well as treatment options, to prevent T2D."

The researchers say that microbiome analysis should not replace existing tests for diabetes or prediabetes. The current findings show associations between particular bacterial patterns and diabetes risk.

The researchers also found that some of the bacteria making up the diabetes-related signature have never been isolated or cultivated in a laboratory and are new in terms of scientific investigation.

Additional research will be needed to assess whether these microbial changes can reliably predict who will develop diabetes and whether changing the microbiome can actually reduce that risk.

A Type 2 diabetes diagnosis increases the risk of developing chronic kidney disease (CKD) or heart failure (HF), or dying, by 55% within 10 years, according to analysis of data from more than 1.6 million patients across the US.

Within the first five years of a Type 2 diabetes diagnosis, the study found that the combined risk of developing CKD or heart failure, or dying, was 33% on average. By year 10, that combined risk rises to 55%.

Key Findings

The study shows within five years of a first diabetes diagnosis, the risk of developing CKD first was more than twice that of developing heart failure first (19.0% vs. 8.3%).

However, among people who developed heart failure first, there was a 42% risk of developing CKD within the following five years.

Conversely, among those who developed CKD first, there was a 23% risk of developing heart failure within the following five years.

"Our findings clearly show how the serious complications associated with type 2 diabetes rise sharply over time as the common combination of obesity, abnormal blood fats, high blood pressure and higher blood sugar damages blood vessels and vital organs," said Professor Naveed Sattar of the University of Glasgow in Scotland, UK.

Why The Findings Matter

Type 2 diabetes is projected to become the world's most prevalent epidemic disease, affecting an estimated 1.3 billion people by 2050.

It frequently occurs alongside obesity, high blood pressure, heart failure, CKD and depression, contributing substantially to the global burden of multi-morbidity.

The researchers say the findings highlight the importance of early, proactive and holistic management of Type 2 diabetes to help reduce the risk of serious complications.

"Our results emphasize the critical importance of detecting and treating type 2 diabetes thoroughly at the earliest opportunity to help reduce the risk of serious complications," Sattar added.

How Was The Study Conducted?

The team included 1,617,508 patients newly diagnosed with diabetes between January 1, 2010, and March 31, 2024, from across the US.

The average age of participants at enrollment was 59, and 51% were female. Among the 13% of patients who had a body mass index (BMI) recorded, the median was 30.9 kg/m².

Almost three-quarters (72%) of participants were living with dyslipidemia, or high levels of cholesterol and other fats in the blood, while more than two-thirds (68%) had high blood pressure.

How Are Diabetes, Kidney Disease And Heart Failure Linked?

The US Centers for Disease Control and Prevention (CDC) explains that diabetes, CKD and heart disease are interconnected.

High blood sugar can gradually damage the kidneys, reducing their ability to filter blood and potentially leading to CKD. When kidney function declines, it can also put additional stress on the heart.

Common Risk Factors

Risk factors that can overlap across diabetes, CKD and heart disease include:

• High blood sugar
• High blood pressure
• Family history
• Obesity
• Unhealthy diet
• Physical inactivity

Tips To Prevent

The CDC recommends lifestyle measures that can help reduce the risk of these conditions and their complications:

• Get active
• Choose healthy foods and drinks
• Quit smoking